Phase 1 Trial Update
Single ascending doses tested so-far
• Well tolerated
• No safety concerns so-far
• Showing excellent pharmaceutic properties
• Multiple ascending dose expected to start soon
• On track to complete dosing in Q2 2021
Well tolerated, no safety concerns, showing excellent pharmaceutical properties.
We are certainly on the right track ... so far so good
Excellent ...
.
Ann: Investor Update - February 2021, page-3
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.4¢ |
Change
-0.001(1.05%) |
Mkt cap ! $25.83M | |||
| Open | High | Low | Value | Volume |
| 9.5¢ | 10.0¢ | 9.4¢ | $176.0K | 1.800M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 129487 | 9.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.9¢ | 37750 | 2 |
View Market Depth
| Last trade - 16.10pm 05/09/2024 (20 minute delay) ? |
| ATX (ASX) Chart |